6-K

---

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the Month of July 2024

Commission file number 001- 41291

---

MeihuaInternational Medical Technologies Co., Ltd.

(Translation of registrant’s name into English)

88 Tongda Road, Touqiao Town

Guangling District, Yangzhou, 225000

People’s Republic of China

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒      Form 40-F ☐

Share Repurchase Plan

On June 26, 2024, the board of directors (the “Board”) of Meihua International Medical Technologies Co., Ltd. (the “Company”) approved and authorized the Company’s proposal to adopt a share repurchase plan of up to $3 million of the Company’s outstanding ordinary shares (the “Share Repurchase Plan”). Under the Share Repurchase Plan, management is authorized to purchase ordinary shares from time to time through open market purchases or privately negotiated transactions at prevailing prices as permitted by securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy, and subject to market conditions and other factors.

Following the Board’s approval, the Company engaged Tiger Brokers (NZ) Limited (“Tiger Brokers”) as the Company’s exclusive repurchase agent for the Share Repurchase Plan. In conjunction with the Share Repurchase Plan, and as approved by the Board, the Company also intends to implement a 10b5-1 plan (the “10b5-1 Plan”) with Tiger Brokers. The Company intends to implement the Share Repurchase Plan and the 10b5-1 Plan sometime after it files its Semi-Annual Report on Form 6-K for the period ending June 30, 2024. The adoption of the Share Repurchase Plan and the 10b5-1 Plan does not obligate the Company to acquire any particular amount of ordinary shares and such plans may be suspended or discontinued at any time by the Board. The form of the Share Repurchase Plan and the Rule 10b5-1 Plan are attached hereto as Exhibits 99.2 and 99.3, respectively.

---

Amended and Restated Insider Trading Policy

On June 26, 2024, the Board adopted an amended and restated insider trading policy, (the “A&R Insider Trading Policy”) which became effective immediately upon adoption. The Company believes that adopting the A&R Insider Trading Policy will reinforce and strengthen the Company’s corporate governance efforts in preventing insider trading, comply with securities laws, and preserve the reputation and integrity of the Company as well as that of all persons affiliated with the Company.

A copy of the A&R Insider Trading policy is attached hereto as Exhibit 99.3. The A&R Insider Trading Policy will also be posted on the Company’s website.

---

EXHIBIT INDEX

Exhibit No.	Description
99.1	Form of Share Repurchase Plan
99.2	Form of Rule 10b5-1 Repurchase Plan
99.3	Amended and Restated Insider Trading Policy
99.4	Press Release dated July 1, 2024

1

SIGNATURES

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Meihua International Medical Technologies Co., Ltd.
Dated: July 1, 2024
	By:	/s/ Xin Wang
	Name:	Xin Wang
	Title:	Chief Executive Officer
		(Principal Executive Officer)

2

Exhibit99.1

June 26, 2024

Meihua International Medical Technologies Co., Ltd.

Attn: Xin Wang, Chief Executive Officer

88 Tongda Road, Touqiao Town, Guangling District

Yangzhou, China 2250000

Dear Yongjun Liu:

In exchange for the opportunity to act as agent on behalf of Meihua International Medical Technologies Co., Ltd. (the “Company”) in connection with its program to repurchase ordinary shares (the “Securities”), which represent ordinary shares of the Company and are listed on the Nasdaq under the symbol “MHUA,” we make the following representations to you, each of which relates to our conduct when we act as your agent with respect to the program:

●	We<br> agree to use our best efforts to effect all open-market purchases in accordance with the<br> purchasing conditions of Rule 10b-18 promulgated under the Securities Exchange Act of 1934,<br> as amended (“Rule 10b-18”), unless we are otherwise instructed you or your designees.
●	We<br> will promptly follow all instructions provided to us by you or your designees as to the timing,<br> price, and volume of purchases that we make; provided that if such purchases are executed<br> pursuant to a written plan complying with the provisions of SEC Rule 10b5-1 (a “10b5-1<br> Plan”), then all timing, price, and volume of purchases that we make shall be governed<br> solely by the terms of such 10b5-1 Plan.
---	---
●	The<br> individuals specified on Attachment A will be responsible for complying with your trading<br> instructions. Attachment A also provides each such individual’s telephone number, fax<br> number, email address and area of responsibility.
---	---
●	We will provide you with an email report on each trade date, detailing the number of ADSs purchased, the prices at which ADSs were purchased, the principal dollar amount of such transactions, the commissions, the net dollar amount due to us, the trade date and the settlement date. Official confirmations will be generated overnight and sent via regular mail.
---	---
●	We<br> will execute all trades at a commission rate of $[0.01186] per share purchased, subject<br> to a minimum fee of $[2.99] per order.
---	---
●	Payment<br> for Ordinary Shares purchased, together with any applicable fees and commissions, shall be<br> deducted by us from your pre-deposit in the account to be established for the purpose of<br> effecting repurchases on behalf of you.
---	---

In order to facilitate the above representations by us, the Company agrees that it will:

●	Provide<br> us with a secretary’s certificate (or equivalent document) that identifies, and includes<br> specimen signatures of, all individuals (“Authorized Persons”) authorized to<br> establish, maintain, transact in and instruct us on the brokerage account to be established<br> for the purpose of effecting repurchases on behalf of the Company;
●	Provide<br> us with a Form W-8BEN-E certifying the taxpayer identification number of the entity repurchasing<br> Ordinary Shares;
---	---
●	Provide<br> us with trade reporting instructions, as outlined in Attachment B, for the daily trade reporting<br> email and account statements;
---	---
●	If<br> applicable, provide us with a list of designees on Attachment C, each of whom will be authorized<br> to instruct us in connection with the program. In the event you as signatory to this framework<br> agreement are a designee on Attachment C, Attachment C must also include a raised corporate<br> seal or signature from an Authorized Person;
---	---
●	If<br> applicable, provide us with all necessary information regarding any previous purchases executed<br> by the Company, as may be required for us to calculate the Company’s volume limitations<br> under Rule 10b-18;
---	---
●	Avoid taking any action that would violate, or would cause any purchase of the ADSs by us to violate, Rule 10b-18, Rule 10b5-1 as applicable or any other applicable law.
---	---

Your execution of this framework agreement constitutes your representation that you are authorized by the Company and are thereby authorizing us to open and maintain for you, an account for the purchase of the ADSs and for any other transactions for which the account may be used, that the designees whose names are set forth on Attachment C, in addition to the Authorized Person, are authorized by the Company to give written and/or oral instructions to us in connection with such transactions and that your execution and performance in accordance with the terms of this framework agreement have been duly authorized on the Company’s behalf by all necessary corporate action.

This framework agreement, along with any 10b5-1 Plan entered into between the parties, constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes any previous agreements, promises, and representations, whether written or oral, between parties. In the event of any conflict between the provisions of such 10b5-1 Plan and the provisions of this framework agreement, the provisions of such 10b5-1 Plan shall control.

The Company acknowledges and agrees that this framework agreement is a “securities contract,” as such term is defined in Section 741(7) of Title 11 of the United States Code, as it may be amended (the “Bankruptcy Code”), entitled to all of the protections given such contracts under the Bankruptcy Code.

This framework agreement will be governed by, and construed in accordance with, the laws of the State of New York, without regard to such State’s conflict of laws rules.

This framework agreement may be executed in two or more counterparts and by facsimile signature.

Please confirm your agreement with the foregoing by signing and returning one copy of this letter to the undersigned, and this framework agreement shall become effective on the date on which:

(i)	The framework agreement shall be signed by both the Company<br>and TIGER BROKERS (NZ) LIMITED; and
(ii)	The Company shall disclose information with respect to tits<br>repurchase program in its public filings as required by the Securities Exchange Act of 1934, as amended, or any applicable rules and<br>regulations.
---	---

[Remainderof page intentionally left blank]

2

IN WITNESS WHEREOF, the undersigned have accepted and agreed to as of the date first written above.

MEIHUA INTERNATIONAL		TIGER BROKERS (NZ) LIMITED
MEDICAL TECHNOLOGIES CO., LTD.
By:	/s/ Yongjun Liu	By:	/s/ Vincent Cheung
Name:	Yongjun Liu	Name:	Vincent Cheung
Title:	Chairman	Title:	CEO

3

AttachmentA

---

TBNZContact List – Special Equity Transactions Group

Origination	Email	Telephone	Fax
Trading	[email protected]
Operations	[email protected]

4

AttachmentB

---

DailyTrade Reporting

---

Recipientsof daily execution report:

****<br><br> <br>Name	Email Address	Telephone
Xin Wang	[email protected]

---

Contactinformation for account statements, confirmations, etc:

Contact:
Mailing Address:
Phone:

---

WireInstructions

Receiving Bank:

ABA #:

For Credit To:

A/C #:

For Further Credit To:

A/C #:

---

5

AttachmentC

---

MeihuaInternational Medical Technologies co., Ltd. Designee List

---

Name	Position / Office	Signature	Telephone
Xin Wang	Chief Executive<br> Officer
Yongjun<br> Liu	Chairman<br> of the Board

---

Signature of Authorized Person
(if necessary)

---

6

---

Exhibit 99.2

---

10b5-1/10b-18 PURCHASE PLAN AGREEMENT

June 26, 2024

Meihua International Medical Technologies Co., Ltd.

Attn: Xin Wang, Chief Executive Officer

88 Tongda Road, Touqiao Town, Guangling District

Yangzhou, China 2250000

This letter agreement (this “Letter Agreement”) confirms the terms and conditions under which Meihua International Medical Technologies Co., Ltd., a Cayman Islands limited company (the “Purchaser”), hereby establishes a plan (the “Plan”) to purchase Ordinary Shares (the “Securities” or “ADS”) of the Purchaser itself, and under which TIGER BROKERS (NZ) LIMITED (“TBNZ”) will act as its exclusive agent to execute the Plan.

1.	Appointment<br> of TBNZ. The Purchaser hereby appoints TBNZ as its exclusive agent to purchase Securities<br> pursuant to the Plan. It is the Purchaser’s intention that such purchases benefit from<br> the safe harbor provided by Rule 10b-18 (“Rule 10b-18”) and the affirmative defense<br> provided by Rule 10b5-1 (“Rule 10b5-1”) each promulgated by the Securities and<br> Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as<br> amended (the “Exchange Act”), and that the Plan and the transactions contemplated<br> hereby comply with the requirements of paragraph (c)(1)(i)(B) of Rule 10b5-1. Accordingly,<br> the Purchaser hereby agrees that the terms of this Letter Agreement and the Plan shall be<br> interpreted to comply with the requirements of such paragraph (c)(1)(i)(B). TBNZ agrees that<br> it shall use good faith efforts to execute all purchases of Securities under this Letter<br> Agreement in accordance with the timing, price and volume restrictions contained in subparagraphs<br> (2), (3) and (4) of paragraph (b) of Rule 10b-18, taking into account the<br> rules and practices of the principal exchange on which the Securities are traded (the “Principal<br> Market”), it being understood that TBNZ shall not be responsible for delays between<br> the execution and reporting of a trade in the Securities, any reporting errors of the Principal<br> Market or third party reporting systems or other circumstances beyond TBNZ’s control.
2.	Term.
---	---
(a)	TBNZ<br> is authorized to commence purchasing Securities on July 1, 2024 (the “Start Date”)<br> and shall continue such purchases on each of the operative dates set forth in Annex A, herein,<br> when the Principal Market is open for business and the Securities trade regular way on the<br> Principal Market (each a “Purchaser Trading Day”). This Letter Agreement and<br> the Plan shall terminate upon the earliest of (the period from and including the Start Date<br> to such termination, the “Plan Period” “Purchase Period”):
---	---
(i)	the 6 months anniversary of the date Start Date;
---	---
(ii)	the<br> completion of all purchases contemplated by the Plan;
---	---
(iii)	subject<br> to Section 12 below, the receipt by either party from the other of written notice of termination;
---	---
(iv)	the<br> existence of any legal or regulatory restriction that would prohibit any purchase pursuant to the Plan;
---	---
(v)	the<br> public announcement (as defined in Rule 165(f) under the Securities Act of 1933, as amended) of any merger, acquisition, or similar<br> transaction relating to the Purchaser (other than any such transaction in which the Purchaser is the acquiring party and the consideration<br> consists solely of cash and there is no valuation period);
---	---
(vi)	the<br> commencement of any voluntary or involuntary case or other proceeding seeking liquidation, reorganization or other relief with respect<br> to the Purchaser under any bankruptcy, insolvency or similar law or seeking the appointment of a trustee, receiver or other similar<br> official with respect to the Purchaser, or the taking of any corporate action by the Purchaser to authorize or commence any of the<br> foregoing; and
---	---
(vii)	the<br> failure of the Purchaser to comply with Section 7 hereof.
---	---
(b)	If,<br> as contemplated by paragraph (a)(iv) of this Section 2, at any time during the term<br> of this Letter Agreement, any legal or regulatory restriction that is applicable to the Purchaser<br> or its affiliates would prohibit any purchase pursuant to the Plan, the Purchaser shall give<br> TBNZ notice of such restriction as soon as practicable (such notice, a “Required Termination<br> Notice”). Such notice shall not include any information about the nature of the restriction<br> or its applicability to the relevant entity.
---	---
(c)	The<br> Purchaser shall be solely responsible for any purchases made by TBNZ as the Purchaser’s<br> agent prior to the termination of the Plan. In addition, if TBNZ receives notice of termination<br> (including any Required Termination Notice) or of any of the termination events listed above,<br> TBNZ shall nevertheless be entitled to make, and the Purchaser shall be solely responsible<br> for, a purchase hereunder pursuant to a bid made before such notice was received by TBNZ.
---	---
(d)	Sections<br> 7 and 11 of this Letter Agreement shall survive any termination hereof.
---	---
3.	Purchases<br> Outside Plan. The Purchaser agrees that it shall not, and represents and warrants to<br> TBNZ that all of its “affiliated purchasers” (as defined in Rule 10b-18) have<br> agreed with the Purchaser that they shall not (i) directly or indirectly purchase, offer<br> to purchase or place any bid or limit order for the purchase of any Securities or any securities<br> convertible or exchangeable into or exercisable for, or the value of which is derived from,<br> the Securities on a Purchaser Trading Day except under the Plan pursuant to this Letter Agreement,<br> or (ii) enter into any similar purchase plan or any derivative transaction, accelerated<br> share repurchase transaction or other transaction with a purchase period, valuation period,<br> calculation period or similar period during which the Purchaser’s or such “affiliated<br> purchaser’s” (as defined in Rule 10b-18), as the case may be, counterparty to<br> such plan or transaction could reasonably be expected to purchase Securities, which period<br> overlaps with a Purchaser Trading Day. If the Purchaser becomes aware that any “affiliated<br> purchaser” (as defined in Rule 10b-18) of the Purchaser itself has taken any such action<br> during the Plan Period, the Purchaser shall so notify TBNZ as soon as practicable.
---	---
4.	Purchasing<br> Procedures.
---	---

(a) On each Purchaser Trading Day during the Plan Period on which no Market Disruption Event (as defined below) occurs, TBNZ shall use commercially reasonable efforts to purchase as agent for the Purchaser and for the account of the Purchaser the lesser of (i) the maximum number of Securities that the Purchaser could purchase on such Purchaser Trading Day in accordance with the volume condition set forth in Rule 10b-18 and (ii) the number of Securities that TBNZ is able, subject to market conditions and principles of best execution, to purchase as agent for the Purchaser and for the account of the Purchaser on such Purchaser Trading Day using commercially reasonable means in accordance with the Plan guidelines set forth in Annex A hereto. TBNZ may purchase Securities on the Principal Market, any national securities exchange, in the over-the-counter market, on an automated trading system or otherwise. Any numbers of Securities to be purchased (and any corresponding purchase price limits or ranges) set forth in Annex A shall be adjusted automatically on a proportionate basis to take into account any stock split, reverse stock split or stock dividend with respect to the Securities or any change in capitalization with respect to the Purchaser or any similar event that occurs during the term of this Letter Agreement, as determined by TBNZ in good faith and a commercially reasonable manner.

2

“Market Disruption Event” means that (i) there occurs any material (as reasonably determined by TBNZ) suspension of or limitation on trading by the Principal Market, (ii) there occurs any event that materially (as reasonably determined by TBNZ) disrupts or impairs the ability of market participants in general to effect transactions in or obtain market values for the Securities or futures or options contracts on the Securities or (iii) the Principal Market closes prior to its scheduled closing time for such trading day.

(b) In the event that TBNZ, in its discretion, determines that it is appropriate with regard to any legal, regulatory or self-regulatory requirements or related internal policies and procedures (whether or not such requirements, policies or procedures are imposed by law or have been voluntarily adopted by TBNZ) for TBNZ to refrain from purchasing Securities or to purchase fewer than the number of Securities otherwise specified in the instructions provided by the Purchaser on any Purchaser Trading Day, then TBNZ may, in its sole discretion, elect that the number of Securities purchased shall be reduced for such day to an amount determined by TBNZ in its discretion.

(c) Any Securities purchased pursuant to the Plan shall be purchased under ordinary principles of best execution at the then-prevailing market price. Subject to the terms of the Plan as set forth herein (including Annex A hereto), TBNZ shall have full discretion with respect to the execution of all purchases, and the Purchaser acknowledges and agrees that the Purchaser does not have, and shall not attempt to exercise, any influence over how, when or whether purchases of Securities are effected pursuant to the Plan. The Purchaser acknowledges and agrees that, in purchasing Securities pursuant to the Plan, TBNZ will be an independent contractor and will not be acting as the Purchaser’s trustee or fiduciary or in any similar capacity.

5.	Payment<br> for and Delivery of Purchased Securities. Payment for Securities purchased, together<br> with any applicable fees and commissions, shall be deducted by TBNZ from the Purchaser’s<br> pre-deposit in the account to be established for the purpose of effecting repurchases on<br> behalf of the Purchaser.
6.	Compensation. For the services provided in this Letter Agreement, the Purchaser agrees to pay to TBNZ a fee of $[0.01186] per share, subject to a minimum fee of $[2.99] per order, for the Securities purchased pursuant to the terms of this Letter Agreement.
---	---
7.	Representations,<br> Warranties and Agreements. The Purchaser represents and warrants to, and agrees with,<br> TBNZ as follows:
---	---

(a) This Letter Agreement and the transactions contemplated herein have been approved, to the extent required, pursuant to or under any and all applicable policies and procedures of the Purchaser applicable to purchases of Securities by the Purchaser itself; this Letter Agreement is the valid and binding agreement of the Purchaser, enforceable in accordance with its terms; performance of the transactions contemplated herein will not violate any law, rule, regulation, order, judgment or decree applicable to the Purchaser or conflict with or result in a breach of or constitute a default under any agreement or instrument to which the Purchaser is a party or by which it or any of its property is bound; and no governmental, administrative or official consent, approval, authorization, notice or filing is required for performance of the transactions contemplated herein.

(b) As of the date of this Letter Agreement, the Purchaser is not aware of any material nonpublic information concerning the Securities or the business, operations or prospects of the Purchaser itself.

(c) The Purchaser is engaging TBNZ and entering into this Letter Agreement and the Plan in good faith and not as part of a plan or scheme to evade compliance with the federal securities laws, including, without limitation, Rule 10b-5 under the Exchange Act. Until this Letter Agreement is terminated, the Purchaser agrees not to enter into or alter any corresponding or hedging transaction or position with respect to the Securities. The Purchaser guarantees and confirms that (1) the trading (if any) of the Purchaser’s securities accounts for the Purchaser’s share incentive plans (the “Securities Accounts”) (if any) follows on the instructions of any person who has been granted an award pursuant to the share incentive plans adopted by the Purchaser (“Participants”) or the Participants’ authorized persons rather than Purchaser’s own instructions and (2) the trading (if any) of the Securities Accounts (if any) is on behalf of the Participants rather than the Purchaser during the Purchase Period.

(d) The Purchaser is not entering into this Letter Agreement to create actual or apparent trading activity in the Securities (or any security convertible into or exchangeable for the Securities) or to raise or depress the price of the Securities (or any security convertible into or exchangeable for the Securities) for the purpose of inducing others to buy or sell Securities, and will not engage in any other securities or derivative transaction to such ends.

3

(e) During the term of this Letter Agreement, the Purchaser shall not, directly or indirectly, disclose to any person at TBNZ effecting purchases under the Plan any material nonpublic information regarding the Purchaser itself or the Securities or any information regarding the Purchaser itself or the Securities that could reasonably be expected to influence the execution of the Plan.

(f) The Purchaser acknowledges that TBNZ is a “financial institution” and “financial participant” within the meaning of Sections 101(22) and 101(22A), respectively, of Title 11 of the United States Code (the “Bankruptcy Code”). The parties hereto further agree and acknowledge that each transaction under this Letter Agreement is intended to be a “securities contract” as defined in Section 741(7) of the Bankruptcy Code and each payment or delivery of cash, Securities or other property or assets hereunder is a “settlement payment” within the meaning of Section 741(8) of the Bankruptcy Code, and the parties hereto are to be entitled to the protections afforded by, among other Sections, Sections 362(b)(6), 362(b)(27), 362(o), 546(e), 546(j), 555 and 561 of the Bankruptcy Code.

(g) Prior to 8:00 a.m., New York City time on the Start Date, the Purchaser shall provide to TBNZ all information, including without limitation publicly reported trading volumes, necessary for TBNZ to calculate the maximum number of Securities that may be purchased as of the Start Date in accordance with the volume condition set forth in Rule 10b-18, and TBNZ shall be entitled to rely on such information so provided.

(h) The Purchaser agrees, and represents and warrants to TBNZ that the Purchaser’s respective affiliates and agents, has agreed with the Purchaser, (i) that no action shall be taken that would cause Regulation M under the Exchange Act (“Regulation M”) to be applicable to any purchases of Securities, or any security for which the Securities are a reference security (as defined in Regulation M), by the Purchaser or any other affiliated purchasers (as defined in Regulation M) of the Purchaser during the Plan Period; and (ii) that no action shall be taken, or permitted by the Purchaser to be taken, that could jeopardize the availability of Rule 10b-18 for purchases of Securities under the Plan or result in such purchases not so complying with the requirements of paragraph (c)(1)(i)(B) of Rule 10b5-1.

(i) The Purchaser shall be solely responsible for compliance with all statutes, rules and regulations applicable to the Purchaser and the transactions contemplated hereby, including, without limitation, reporting and filing requirements. The Purchaser acknowledges and agrees that it is not relying, and has not relied, upon TBNZ or any affiliate of TBNZ with respect to the legal, accounting, tax or other implications of the Plan and the transactions contemplated thereby and that it has conducted its own analyses of the legal, accounting, tax and other implications hereof.

(j) The Purchaser acknowledges ad agrees that TBNZ shall impose trading restrictions on the account of the Purchaser for the Plan and TBNZ shall not be responsible for any loss incurred as a result of or arising from such restrictions.

TBNZ has made no representation and has no obligation with respect to whether the Plan or the transactions contemplated thereunder qualify for the safe harbor provided by Rule 10b-18 or the affirmative defense provided by Rule 10b5-1.

8.	Disclosure<br> of Acquisition Program. The Purchaser represents and warrants that it has publicly disclosed<br> its intention to acquire the Securities.
9.	Other<br> Purchases by TBNZ. Nothing herein shall preclude the purchase by TBNZ of Securities for<br> TBNZ’s own account, or the solicitation or execution of purchase or sale orders of<br> Securities for the account of TBNZ’s clients.
---	---
10.	Indemnification.<br> The Purchaser shall indemnify TBNZ and its affiliates against any liabilities or expenses<br> (including attorney’s fees and disbursements), or actions in respect of any liabilities<br> or expenses, arising from the services furnished pursuant to this Letter Agreement including,<br> but not limited to, liabilities and expenses arising by reason of any violation or alleged<br> violation of any state or federal securities laws, except to the extent such liabilities<br> or expenses result from the gross negligence or bad faith of TBNZ or its affiliates. The<br> Purchaser shall also promptly reimburse TBNZ and its affiliates for all expenditures (including<br> attorney’s fees and disbursements) made to investigate, prepare or defend any action<br> or claim in respect of any such liability or expense, regardless of whether any litigation<br> is pending or threatened against TBNZ or its affiliates.
---	---

4

11.	Amendment,<br> Modification, Waiver or Termination. Any amendment, modification, waiver or termination<br> of this Letter Agreement or the Plan, including without limitation any election by the Purchaser<br> to terminate this Letter Agreement or the Plan, must be effected in accordance with the requirements<br> for the amendment or termination of a “plan” as defined in paragraph (c) of<br> Rule 10b5-1, and only with TBNZ’s written consent. Without limiting the generality<br> of the foregoing, any such amendment, modification or waiver shall be made in good faith<br> and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Exchange<br> Act, and no such amendment, modification, waiver or termination shall be made at any time<br> at which the Purchaser is aware of any material nonpublic information concerning the Purchaser<br> itself or the Securities. The Purchaser will be deemed to repeat its representations in Section<br> 7 at the time of such amendment, modification, or waiver. The Purchaser acknowledges and<br> agrees that any action taken by it that results in the termination of the Plan pursuant to<br> Section 2 is subject to the principles set forth in this section. The Purchaser’s<br> payment obligation under Section 6 hereof in respect of any Securities purchased prior to<br> any termination of this Letter Agreement shall survive any such termination.
12.	Notices.<br> Any written communication shall be sent to the address specified below: and shall become<br> effective upon receipt:
---	---
(a)	if<br> to TBNZ, to it at
---	---

TIGER BROKERS (NZ) LIMITED

Level 27,151 Queen Street

Auckland Central, Auckland 1010

Attention: Chaofan Zhang

Telephone: +86 185 1392 2284

or at such other address as may from time to time be designated by notice to the Purchaser in writing; and

(b)	if to<br> the Purchaser, to it at

Meihua International Medical Technologies Co., Ltd.

88 Tongda Road, Taoqiao Town, Guangling District

Yangzhou, China 225000

Attention: Yongjun Liu

Telephone: +86-13905273399

or at such other address as may from time to time be designated by notice to TBNZ in writing.

13.	Assignment.<br> Neither party may assign its rights and obligations under this Letter Agreement to any other<br> party; provided that TBNZ may assign its rights and obligations under this<br> Letter Agreement to any subsidiary of UP Fintech Holding Limited, as permitted under applicable<br> laws.
14.	Governing Law. This Letter Agreement and any claim relating hereto shall be governed by and<br> construed in accordance with the laws of the State of New York. The parties hereto irrevocably submit to the non-exclusive jurisdiction<br> of the Federal and state courts located in the Borough of Manhattan, in the City of New York in any suit or proceeding arising our<br> of or relating to this Letter Agreement or the transactions contemplated hereby. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY AND ALL<br> RIGHTS TO TRIAL BY JURY WITH RESPECT TO ANY LEGAL PROCEEDING ARISING OUR OF OR RELATING TO THIS LITTER AGREEMENT OR ANY TRANSACTION<br> CONTEMPLATED HEREBY.
---	---
15.	This Letter Agreement (including<br> any annexes, exhibits, or appendices) along with the framework agreement dated June 26, 2024 (“Framework Agreement”)<br> constitutes the entire agreement between the parties with respect to the subject matter hereof, and supersedes any previous agreements,<br> understandings, proposals or promises with respect thereto, whether written, oral or otherwise. In the event of a conflict between<br> the terms and conditions of this Letter Agreement and the terms and conditions of the Framework Agreement, the terms and conditions<br> of this Letter Agreement shall govern.
16.	This Letter Agreement may<br> be executed in two or more counterparts and by facsimile signature.

5

If the foregoing correctly sets forth our agreement, please sign the form of acceptance below.

TIGER BROKERS (NZ) LIMITED
By:	/s/ Vincent Cheung
	Name:	Vincent Cheung
	Title:	CEO

Agreed to and accepted as of: June 26, 2024

Meihua International Medical Technologies Co., Ltd.
By:	/s/<br> Yongjun Liu
	Name:	Yongjiu Liu
	Title:	Chairman

6

---

ANNEX A (version1)

The Purchaser hereby authorize TBNZ to use its Tiger account [   ] for purchases and relevant operations under the Plan according to the specifics in Annex A of this Letter Agreement.

The Purchaser shall send the complete operating specifics of the Plan (including, at least, the purchase period, daily share cap and maximum purchase price) to TBNZ. Communications contemplated herein shall be sent from/to the email address specified below:

TBNZ:	The<br> Purchaser:
[email<br> address]	[email<br> address]

Upon TBNZ’s receipt of the complete operating specifics (or if the operating specifics was sent in several emails, upon TBNZ’s receipt of the last email that completes the operating specifics), the complete operating specifics shall be deemed to be incorporated into Annex A of this Letter Agreement, and take effect from such incorporation, provided that such complete instructions are sent during the Purchaser’s trading window period (determined pursuant to the Purchaser’s insider trading policies).

---

7

Exhibit 99.3

MeihuaInternational Medical Technologies Co., Ltd.

---

AMENDED AND RESATED INSIDER TRADING POLICY

---

A.	Background/Purpose

Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of Meihua International Medical Technologies Co., Ltd. (together with its subsidiaries, the “Company”) as well as that of all persons affiliated with the Company. “Insider trading” occurs when any person purchases or sells a security while in possession of inside information relating to the security. As explained in Section F below, “insider information” is information that is both “material” and “non-public.” Insider trading is a crime. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, civil fines, and criminal fines of up to $5 million for individuals and $25 million for corporations. Insider trading is also prohibited by this Insider Trading Compliance Policy (this “Policy”), and violation of this Policy may result in Company-imposed sanctions, including removal or dismissal for cause.

---

The Company has adopted this Policy both to satisfy the Company’s obligation to prevent insider trading and to help the Company’s personnel and its external advisors avoid violating insider trading laws.

---

B.	Applicability of this Policy

---

1.	Covered Persons. This Policy applies to the following people (collectively, “Covered Persons”):

---

●	all officers of the Company;
●	all members of the board of directors of the Company (“Directors”);
●	all employees of the Company; and
●	any family members of the foregoing persons. For the purposes of this Policy, the term “family member” means a spouse, parent, stepparent, child, stepchild, sibling, mother and father-in law, son and daughter-in-law, brother and sister-in-law, and anyone (other than a domestic employee or tenant) who shares the covered person’s home.

The failure of any person subject to this Policy to observe and strictly adhere to the policies and procedures set forth herein at all times will be grounds for disciplinary action, up to and including dismissal. To ensure that the Company confidences are protected to the maximum extent possible, no individuals other than specifically authorized personnel may release material information to the public, or respond to inquiries from the media, analysts, or others outside the Company.

All consultants and outside advisors assisting the Company on sensitive matters are expected to abide by the Policy, although the Company assumes no responsibility with respect to the actions of persons who are not under its direct control. However, the failure of consultants and outside advisers to observe the policies and procedures set forth herein will be grounds for termination of the consultant’s or outside adviser’s relationship with the Company.

2.	Covered Transactions.

This Policy applies to all transactions in the Company’s securities, including ordinary shares (including any securities that are exercisable for, or convertible or exchangeable into, ordinary shares) and any other securities the Company may issue from time to time whether or not pursuant to any benefit plan adopted by the Company.

For purposes of this Policy, the Company considers transactions between Covered Persons and the Company with respect to grants under its equity incentive plan (or, to the extent applicable, granted outside such plan) to be exempt from this Policy. Such transactions include, without limitation, the following:

●	the exercise of options for cash;
●	the exercise of options on a “net exercise” basis pursuant to which an optionee either (i) delivers outstanding ordinary shares to the Company, or (ii) authorizes the Company to withhold from issuance ordinary shares issuable upon exercise of the option, in either case, having a fair market value on the date of exercise equal to the aggregate exercise price; or
---	---
●	the forfeiture to the Company of restricted ordinary shares or stock units to cover withholding tax obligations.

Thus, restrictions contained in this Policy would apply to the sale of the Company’s securities in the open market to pay the exercise price of an option and to the “cashless exercise” effected through a broker or “same day sale” of an option. In addition, any sale of the underlying securities acquired upon the exercise of an option is subject to the Policy. This Policy does not apply to the granting of options or other equity awards.

In addition to the other restrictions set forth in this Policy, the following transactions are strictly prohibited at all times:

●	trading in call or put options involving the Company’s securities and other derivative securities;
●	engaging in short sales of the Company’s securities (i.e., the sale of a security that the seller does not own);
●	engaging in hedging or monetization transactions with respect to the Company’s securities, such as prepaid variable forwards, equity swaps, collars, and exchange funds; and
●	holding the Company’s securities in a margin account.

If you are unsure whether or not a particular transaction is prohibited under this Policy, you should consult with the Chief Financial Officer, prior to engaging in, or entering into, an agreement, understanding or arrangement to engage in, such transaction.

---

C.	General Policy

No Covered Person who is in possession of Inside Information may, either directly or indirectly (including, without limitation, through a family member, friend or entity in which you or any of your family members is a director, officer or controlling equity holder or beneficiary), (i) purchase or sell the Company’s securities, (ii) engage in any other action to take advantage of Inside Information, or (iii) provide Inside Information to any other person outside of the Company, including family and friends.

In addition, Covered Persons may not purchase or sell any securities of any other company, such as a lender, possible acquisition target or competitor of the Company, when in possession of material non-public information concerning any such other company obtained in the course of his or her employment with, or service to, the Company or any of its subsidiaries.

---

D.	Specific Policies
1.	Black-out Periods.
---	---

All Directors and executive officers of the Company and its subsidiaries, as well as certain key employees, as listed on Schedule A hereto (as may be amended from time to time by the Chief Financial Officer), as well as any family members or other persons who reside in the same household as those persons (all of the foregoing being “Restricted Persons”) are subject to additional restrictions on their ability to engage in purchase or sale transactions involving the Company’s securities. Restricted Persons are more likely to have access to Inside Information regarding the Company because of their positions or affiliations with the Company and, as a result, their trades in the Company’s securities are more likely to be subject to greater scrutiny. Accordingly, Restricted Persons are prohibited from trading in the Company’s securities during the period beginning on the 15^th^ day of the last month of each fiscal quarter and ending two (2) trading days following public disclosure of the financial results for that quarter or the full year. Furthermore, a Restricted Person who is in possession of any material nonpublic information should not trade in the Company’s securities until the information has been made publicly available or is no longer material.

2

In addition, from time to time, the Company may impose special black-out periods on Restricted Persons and other employees of the Company if, in the judgment of the Chief Financial Officer, it is likely that such person or persons have become aware of significant corporate developments that have not yet been disclosed to the public, even when trading otherwise may be permitted. In the event that certain Restricted Persons or other employees of the Company become subject to a special black-out period, such persons are prohibited from (i) trading in the Company’s securities, and (ii) disclosing to others the fact they are subject to such special black-out period. These special black-out periods may vary in length and may or may not be broadly communicated to Covered Persons. This restriction does not apply to transactions made under a Rule 10b5-1 plan approved in accordance with a 10b5-1 Pre-Planned Trading Programs Policy adopted by the Company. The Company would re-open trading at the beginning of the 3rd trading day following the date of public disclosure of such significant corporate developments.

2.	“Tipping” of Information.

Covered Persons may not disclose, convey or “tip” Inside Information to any person by providing them with Inside Information other than to disclose on a “need to know” basis to officers and employees of the Company or outside advisors in the course of performing their duties for the Company. When sharing Inside Information with other officers and employees of the Company or outside advisors, or other persons involved in the business and affairs of the Company, such information should be confined to as small a group as possible. Unlawful tipping includes passing on Inside Information to friends, family members or acquaintances under circumstances that suggest that persons subject to this Policy were trying to help the recipients of such information to make a profit or avoid a loss by trading in the Company’s securities based on such information.

3.	Pre-clearance.

Under certain circumstances, the Chief Financial Officer may authorize the immediate release of material non-public information. If disclosure is authorized, the form and content of all public disclosures shall be pre-cleared by the Chief Financial Officer. A Restricted Person must obtain prior clearance from the Chief Financial Officer (or, if the Restricted Person is the Chief Financial Officer, from the Chief Executive Officer) before such Restricted Person makes any purchases or sales of the Company’s securities, regardless of whether or not a black-out period is then in effect. In evaluating each proposed transaction, the Chief Financial Officer (or, if the Restricted Person is the Chief Financial Officer, from the Chief Executive Officer) will consult as necessary with senior management and outside counsel before clearing any proposed trade. Clearance of a transaction is valid for no more than the five (5) business day period immediately following receipt by the Restricted Person of such clearance. If clearance is denied, the fact of such denial must be kept confidential by the person requesting such clearance. Restricted Persons do not need to receive pre-clearance for trades pursuant to a Rule 10b5-1 plan, approved in accordance with a 10b5-1 Pre-Planned Trading Programs Policy adopted by the Company, which is set forth in Schedule B hereto.

---

E.	Compliance

All Covered Persons must promptly report any trading in the Company’s securities by any Covered Person, or any disclosure of Inside Information or material non-public information concerning other companies by such Covered Person, that such person has reason to believe may violate this Policy or federal or state securities laws.

Persons in possession of Inside Information when their employment or service terminates may not trade in the Company’s securities until that information has become public or is no longer material.

F.	Additional Information
1.	What is Inside Information?
---	---

“InsideInformation” is material information about the Company that is not available to the public. Information generally becomes available to the public when it has been disclosed by the Company or third parties in a press release or other authorized public statement, including any filing with the SEC. In general, information is considered to have been made available to the public on the 2^nd^trading day after the formal release of the information. In other words, there is a presumption that the public needs approximately one complete trading day to receive and absorb such information.

3

2.	What is Material Information?

As a general rule, information about the Company is “material” if it could reasonably be expected to affect someone’s decision to buy, hold or sell the Company’s securities. In particular, information is considered to be material if its disclosure to the public would be reasonably likely to affect (i) an investor’s decision to buy or sell the securities of the company to which the information relates, or (ii) the market price of that company’s securities. While it is not possible to identify in advance all information that will be deemed to be material, some examples of such information would include the following:

●	significant changes in financial results and/or financial condition and financial projections;
●	major new contracts or leases, or the possible loss of business;
●	changes in dividend policy, the declaration of a stock split or an offering of additional securities;
●	stock redemption or repurchase programs;
●	changes in management or control;
●	change in auditors or notification that the auditor’s reports may no longer be relied upon;
●	significant mergers, acquisitions, reorganizations, dispositions of assets or joint ventures;
●	significant litigation, investigations, or regulatory developments;
●	significant increases or decreases in the amount of outstanding securities or indebtedness;
●	write-ups or write downs of assets or changes in accounting methods;
●	actual or projected changes in industry circumstances or competitive conditions that could significantly affect the Company’s revenues, earnings, financial position, or future prospects; and
●	transactions with Directors, officers, or principal security holders.

It can sometimes be difficult to know whether information would be considered “material.” The determination of whether information is material is almost always clearer after the fact, when the effect of that information on the market can be quantified. Although you may have information about the Company that you do not consider to be material, federal regulators and others may conclude (with the benefit of hindsight) that such information was material. Therefore, trading in the Company’s securities when you possess non-public information about the Company can be risky. When doubt exists, the information should be presumed to be material. If you are unsure whether you are inpossession of material non-public information, you should consult with the Chief Financial Officer, prior to engaging in, or enteringinto an agreement, understanding or arrangement to engage in, a purchase or sale transaction of any of the Company’s securities.

3.	What is the Penalty for Insider Trading?

Trading on Inside Information is a crime. The consequences of insider trading and tipping are severe and may, in some cases, be applied to the Company as well as to the individual who illegally trades or tips. Possible consequences include criminal prosecution with the potential for prison terms and additional fines if convicted, civil penalties, termination of employment and personal embarrassment resulting from adverse publicity.

If you have any questions with regard to this Policy, you should consult with the Chief Financial Officer.

4

SCHEDULE A

RESTRICTED PERSONS

●	All Directors of the Company;
●	All officers of the Company;
●	All employees of the Company who provide financial or accounting services to the Company; and
●	Any other persons designated by the Chief Financial Officer, from time to time, as set forth below:

---

5

---

SCHEDULE B

RULE 10B5-1 PRE-PLANNED TRADING PROGRAMS

---

1.	Introduction

The Company has adopted a written Policy on Inside Information and Insider Trading (the “Insider Trading Policy”), to which this “Rule10b5-1 Pre-Planned Trading Programs” is an attachment, containing certain basic principles and policies concerning the trading by officers, directors and employees of the Company in the securities of the Company. This sets forth the Company’s policy concerning Rule 10b5-1 pre-planned trading programs by the Company’s directors, officers and employees who have been pre-cleared by the Chief Financial Officer as provided below.

Notwithstanding any other guidelines contained in the Insider Trading Policy to the contrary, it shall not be a violation of the Insider Trading Policy for the Company’s directors, officers and employees to sell (or purchase) securities of the Company under certain pre-planned trading programs adopted to purchase or sell securities in the future which pre-planned trading programs (i) are in compliance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and (ii) have been pre-cleared in advance, in writing, by the Chief Financial Officer (or, if the person implementing such program is the Chief Financial Officer, by the Chief Executive Officer). To initiate any transactions under this exception, a director, officer or employee (a “person” for purposes of this attachment only) must comply with each of the following elements:

(a) While notin possession of material non-public information, the person must (1) enter into a binding contract to purchase or sell securities; (2) instruct another person to purchase or sell securities for the person’s account; or (3) adopt a written plan for purchasing or selling the securities (a “Trading Program”).

(b) The Trading Program must be in writing and must specify the following: (1) the number of securities to be bought or sold; (2) the prices at which the securities will be bought or sold; and (3) the timing of the purchases or sales. The required information regarding amount, price and date may be included by a formula, algorithm or other means. The insider must refrain from attempting to influence how, when or whether transactions will be made pursuant to the Trading Program.

(c) The Trading Program cannot be entered into as part of a plan or scheme to evade the prohibitions on insider trading under the federal securities laws. Therefore, although modifications to an existing Trading Program are not prohibited, a Trading Program should be adopted with the intention that it will be amended or modified infrequently, if at all, since changes to the Trading Program could raise issues as to the individual’s good faith.

(d) No person purchasing or selling securities under a Trading Program may take (or modify existing) hedging positions to account for his or her planned purchases or sales.

(e) Any person wishing to proceed under the Trading Program exception (or to modify or terminate a previously adopted Trading Program) must first obtain written pre-clearance from the Chief Financial Officer (or, if the person implementing the Trading Program is the Chief Financial Officer, from the Chief Executive Officer). This pre-clearance requirement will permit the Company to review the proposed Trading Program as to compliance with applicable securities laws (including Rule 10b5-1), the Insider Trading Policy and the best interests of the Company, with a view toward avoiding unnecessary litigation and other consequences detrimental to the Company and the person seeking to avail himself or herself of this exception. The Company therefore reserves the right to pre-clear or not pre-clear any proposed Trading Program (or the modification of any existing Trading Program) in its sole and absolute discretion based on, among other factors, policies and criteria adopted by the Company from time to time, market conditions, legal and regulatory considerations, and the potential impact of any such Trading Program on any actual or prospective transactions (including the offering of securities) to which the Company is or may be a party.

6

(f) The Company reserves the right not to pre-clear any proposed Trading Program (or the modification of any existing Trading Program) unless it includes the following elements, as well as such additional terms and conditions as the Company may require from time to time:

●	There is no material non-public information at the time a person wishes to enter into a Trading Program (or to modify or terminate a previously adopted Trading Program). If there is any such material non-public information, the Company may delay its pre-clearance of the Trading Program until the information has been disclosed. The Company may also require an interval between the adoption of the Trading Program and the first trade under such Trading Program.
●	Under appropriate circumstances, the Company may wish to make a public announcement of the Trading Program at the time of adoption.
●	The proposed Trading Program contains procedures to ensure prompt compliance with (i) SEC Rule 144 or Rule 145 under the Securities Act of 1933, as amended, relating to any sales under the Trading Program, and (ii) any suspension of trading or other trading restrictions that the Company determines to impose on sales under a pre-cleared Rule 10b5-1 Trading Program, under applicable law or in connection with an offering by the Company of securities, including without limitation lock-up or affiliate letters required in connection with a proposed merger, acquisition or distribution of Company securities or any restrictions on or suspensions of trading imposed by applicable authorities (including the SEC or other governmental authority, or any stock exchange, automated quotation system or other self-regulated organization that promulgates rules to which the Company is subject from time to time).

(g) Each person understands that the pre-clearance or adoption of a pre-planned selling program in no way reduces or eliminates such person’s reporting obligations, if imposed by any laws or regulations. If any questions arise, such person should consult with his or her own counsel prior to entering into a Trading Program.

7

Exhibit 99.4

Meihua International Medical Technologies Co.,Ltd. Announces Share Repurchase Program of Up to $3 million

YANGZHOU, China, July 1, 2024 -- Meihua International Medical Technologies Co., Ltd. (“MHUA” or the “Company”) (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced today that its board of directors (the “Board”) has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares (the “Share Repurchase Program”). The Company intends to cancel all shares repurchased pursuant to this Share Repurchase Program.

The ordinary shares may be repurchased from time to time through open market purchases or privately negotiated transactions at prevailing prices, in accordance with securities laws and other legal requirements, including Rule 10b-18 and Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, as well as the Company’s insider trading policy, and subject to market conditions and other factors.

“With ongoing efforts to innovate, expand our premium product offerings, and enhance operational efficiency through optimized production processes and the application of AI, we continue to strengthen our business model and generate significant cash flow, which enables us to invest for the long term,” said Xin “Steven” Wang, Chief Executive Officer of Meihua. “This Share Repurchase Program including the planned cancellation of repurchased shares not only underscores our confidence in Meihua’s future growth but also demonstrates our commitment to enhancing shareholder value through concrete actions.”

The adoption of this Share Repurchase Program does not obligate the Company to acquire any specific amount of ordinary shares, and it may be suspended or discontinued at any time by the Board.

The Company expects to implement the Share Repurchase Program and a corresponding 10b5-1 plan following the filing of its Semi-Annual Report on Form 6-K for the period ending June 30, 2024.

---

About Meihua International Medical TechnologiesCo., Ltd.

Meihua International Medical Technologies is a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China. The Company manufactures and sells Class I disposable medical devices, such as HDPE bottles for tablets and LDPE bottles for eye drops, throat strips, and anal bags, and Class II and III disposable medical devices, such as disposable identification bracelets, gynecological examination kits, inspection kits, surgical kits, medical brushes, medical dressing, medical catheters, uterine tissue suction tables, virus sampling tubes, disposable infusion pumps, electronic pumps and anesthesia puncture kits, among other products which are sold under Meihua’s own brands and are also sourced and distributed from other manufacturers. The Company has received an international “CE” certification and ISO 13485 system certification and has also registered with the FDA (registration number: 3006554788) for over 20 Class I products. The Company has served hospitals, pharmacies, medical institutions and medical equipment companies for more than 30 years, providing over 1,000 types of products for domestic sales, as well as over 120 products which are exported to more than 30 countries internationally across Europe, North America, South America, Asia, Africa and Oceania.

For more information, please visit www.meihuamed.com.

Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, and its ability to fully execute on the planned agreement, the Company’s future business development and plans of future business development, including its ability to successfully develop robotic assisted surgery systems and obtain licensure and certification for such systems, financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, fluctuations in general economic and business conditions in China, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, including under the section entitled “Risk Factors” in its annual report on Form 20-F, as well as on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For investor and media inquiries, please contact:

IR Department

---

Email: [email protected]

Tel: +86-0514-89800199

Christensen

---

Yang Song

Email: [email protected]

Tel: +86-010-59001548